Vβ11 fitc

Manufactured by Beckman Coulter

The Vβ11 FITC is a fluorescent-labeled antibody that recognizes the Vβ11 chain of the T cell receptor. It is a tool used in flow cytometry applications to detect and quantify the expression of the Vβ11 chain on the surface of T cells.

Automatically generated - may contain errors

Lab products found in correlation

Vα24 pe, by Beckman Coulter (2 mentions) Cd69 fitc, by BD (1 mentions) Cd31 pe, by BD (1 mentions) Cd56 apc, by BD (1 mentions) Il 17 pe, by Thermo Fisher Scientific (1 mentions) Cd4 fitc, by BioLegend (1 mentions) Cd19 apc cy7, by BioLegend (1 mentions) Cd4 bv421, by BioLegend (1 mentions) Ifn γ fitc, by BD (1 mentions) Il 2 pe, by BioLegend (1 mentions) Cd107a pe, by BD (1 mentions) Cd4 pe cy7, by Beckman Coulter (1 mentions) Cd21 pe cy7, by BioLegend (1 mentions) Cd21 pe cy7, by BD (1 mentions) Cd45 pacific blue, by Beckman Coulter (1 mentions) Ccr7 pe, by R&D Systems (1 mentions) Il 4 apc, by Thermo Fisher Scientific (1 mentions) Igm alexa fluor 647, by Jackson ImmunoResearch (1 mentions) Bcl 6, by Leica (1 mentions) Flag tag (flag), by Santa Cruz Biotechnology (1 mentions)

2 protocols using vβ11 fitc

Comprehensive Immune Cell Phenotyping

Check if the same lab product or an alternative is used in the 5 most similar protocols

The following antibodies were used in this study: CD3 AF700, CD4 BV421, CD4 FITC, CD6 APC, CD10 BV605, CD19 APC-Cy7, CD21 PE-Cy7, CD25 PerCP-Cy5.5, CD27 BV421, CD28 PerCP-Cy5.5, CD38 PerCp-Cy5.5, CD45RA APC-Cy7, TCR αβ PerCP-Cy5.5, IL-2 PE, LAT PE, NTAL/LAB APC, and biotin anti–human TCR-Vd2 (BioLegend); TCR-Vd1 APC (Miltenyi Biotec); CD8 APC, CD8 Pacific blue, CD21 PE-Cy7, CD31 PE, CD56 APC, CD69 FITC, CD107a PE, CD127 Alexa Fluor 647, IFN-γ FITC, TCR γδ PE, IgG Alexa Fluor 700, IκBα PE, ERK1/2(pT202/pY204) AF647, and ZAP70(pY319)/SYK(pY352) APC (BD); IgD FITC and IgA PE (SouthernBiotech); CD3 PE-Cy7, CD4 PE-Cy7, CD8 PE, CD16 FITC, CD45RA FITC, CD45 Pacific blue, Vα24 PE, and Vβ11 FITC (Beckman Coulter); CCR7 PE (R&D Systems); Bruton tyrosine kinase/ITK(pY551/pY511) PE, IL-17 PE, IL-4 APC, and ICOS PE (eBioscience); IgM Alexa Fluor 647 (Jackson ImmunoResearch Laboratories, Inc.); and PLCγ1(pY783) and goat anti–rabbit AF647 (Cell Signaling Technology). For immunohistochemistry, CD21 (Dako), CD20 (Invitrogen), CD3 (Cell Marque), CD4 and CD8 (Spring Bioscience), and Bcl-6 (Leica Biosystems) were used. For immunoblotting LAT (sc-7948; Santa Cruz Biotechnology, Inc.), FLAG tag (AHP1074; AbD Serotec), actin (sc-1616; Santa Cruz Biotechnology, Inc.), PLCγ1 (pY783; no. 2821; Cell Signaling Technology), and ZAP70 (pY319; no. 2701; Cell Signaling Technology) were used.

Keller B., Zaidman I., Yousefi O.S., Hershkovitz D., Stein J., Unger S., Schachtrup K., Sigvardsson M., Kuperman A.A., Shaag A., Schamel W.W., Elpeleg O., Warnatz K, & Stepensky P. (2016). Early onset combined immunodeficiency and autoimmunity in patients with loss-of-function mutation in LAT. The Journal of Experimental Medicine, 213(7), 1185-1199.

+ Open protocol

+ Expand

Phenotyping of PBMC Populations

Check if the same lab product or an alternative is used in the 5 most similar protocols

Heparinized peripheral blood samples were collected from the subjects, and mononuclear cells (PBMCs) were obtained by Ficoll gradient centrifugation following the manufacturer's protocol (GE Healthcare Bio‐Sciences AB, Uppsala, Sweden). PBMCs were incubated for 15 min with human γ‐globulins at 4°C for FcR‐blocking. Then, the cells were washed and immediately labeled with specific antibodies or isotype controls for 30 min at 4°C. Specifically, antibodies against the following molecules were used: Vα24‐PE and Vβ11‐FITC (Beckman Coulter, Brea, CA), CD3‐PerCPCy5.5, CD4‐PE, (BioLegend, San Diego, CA), CD8‐PB (BD Pharmingen, Franklin Lakes, NJ), CRTAM‐APC (R&D, Minneapolis, MN), and CD69‐PETR (Beckman Coulter). The following isotype controls were used: IgG1‐PE, IgG2a‐FITC, IgG1‐PErCPCy5.5 (all from BioLegend), IgG1‐PB, (BD Pharmingen), IgG2b‐APC (R&D), and IgG1‐PETR (Beckman Coulter). After incubation, the cells were washed with PBS/2% FBS and were fixed with 4% paraformaldehyde in PBS.

Beristain‐Covarrubias N., Canche‐Pool E., Gomez‐Diaz R., Sanchez‐Torres L.E, & Ortiz‐Navarrete V. (2015). Reduced iNKT cells numbers in type 1 diabetes patients and their first‐degree relatives. Immunity, Inflammation and Disease, 3(4), 411-419.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!